Skip to content
    Jeito Capital logo

    Jeito Capital

    Paris, FranceFounded 2018

    Jeito Capital is a Paris-based independent venture capital firm dedicated to biopharma and biotech, financing and accelerating clinical-stage therapeutic innovation from development to market access. Founded in 2018 by Dr. Rafaèle Tordjman, it closed its second fund at $1.2 billion in 2025, the largest independent biopharma-focused raise in Europe.

    55% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 9 prior). Average disclosed round size is $124.8M (across 31 rounds with reported amounts).

    Find people at Jeito Capital on Goldilocks AI

    Portfolio

    33

    Fund Size

    $1.2B

    Top Stage

    Series B

    Last 12 Mo

    3

    Team

    Sabine Dandiguian

    Sabine Dandiguian

    Managing Partner

    Ksenija Pavletic

    Ksenija Pavletic

    General Partner & Chief Commercial Officer

    Elaine Caughey

    Elaine Caughey

    Partner, Business Development and Investor Relations

    Magdalena Jonikas

    Magdalena Jonikas

    Partner

    Mehdi AINOUCHE

    Mehdi AINOUCHE

    Partner

    Pascal Touchon

    Pascal Touchon

    Operating Partner

    Sarah Shackelton

    Sarah Shackelton

    Partner, Talent

    Ana Leticia Maragno

    Ana Leticia Maragno

    Director of Translational science

    Benjamin CAILLIER

    Benjamin CAILLIER

    Finance Director, Jeito Capital

    Chloé Morlaàs

    Chloé Morlaàs

    Investor Relations Director

    Elsa Fernandez

    Elsa Fernandez

    Finance Director, Fund

    Anastasiya Sybirna

    Anastasiya Sybirna

    Principal

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    56 investments
    CompanyRoundAmountDate
    PPrecirixSeries B—Aug 2026
    Adcendo ApS logoAdcendo ApSSeries C$75MApr 2026
    Alveus Therapeutics Inc logoAlveus Therapeutics IncSeries A$37MFeb 2026
    Aviceda logoAvicedaSeries C—Jan 2026
    AAviceda TherapeuticsUnknown$207.5MJan 2026
    ReproNovo logoReproNovoSeries A$65MMay 2025
    Augustine Therapeutics logoAugustine TherapeuticsSeries A—Mar 2025
    Callio Therapeutics logoCallio TherapeuticsSeries A$187MMar 2025
    Xylocor logoXylocorSeries B$67.5MJan 2025
    AAviceda TherapeuticsSeries C—Jan 2025
    XyloCor Therapeutics logoXyloCor TherapeuticsSeries B$67.5MJan 2025
    Augustine Therapeutics logoAugustine TherapeuticsSeries A—Jan 2025
    Noema Pharma logoNoema PharmaSeries B—Dec 2024
    Alentis Therapeutics logoAlentis TherapeuticsSeries D$181.4MNov 2024
    AAlentisSeries D$181.4MNov 2024
    Catalym logoCatalymSeries D$150MJul 2024
    HHI-BioSeries B$95MJan 2024
    Noema logoNoemaSeries B—Jan 2024
    Alentis Therapeutics logoAlentis TherapeuticsSeries D$181.4MJan 2024
    AAlentisSeries D$181.4MJan 2024
    NMD Pharma logoNMD PharmaSeries B—Nov 2023
    Corteria Pharmaceuticals logoCorteria PharmaceuticalsSeries A—Sep 2023
    Noema logoNoemaSeries B—Mar 2023
    Noema Pharma logoNoema PharmaSeries B—Mar 2023
    CCorteriaSeries A—Jan 2023
    Page 1 of 3

    Top Co-Investors

    Last updated: 20 October 2026